Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study
Tóm tắt
Ritodrine hydrochloride (RD), a β2-adrenergic agonist, is widely used as a tocolytic medication to suppress premature labor, but can cause neonatal hypoglycemia, a potentially severe side effect. We examined the incidence and risk factors of neonatal hypoglycemia following maternal intravenous administration of RD. This was a retrospective study of neonates, who had birth weight of ≥2000 g and were delivered at 36 weeks gestation or later in Kanazawa University Hospital from August 2013 to July 2016. We defined neonatal hypoglycemia as blood glucose level < 50 mg/dL. Neonates who were delivered without maternal intravenous RD or who were delivered 8 days or more after stopping maternal RD or who received oral RD were defined as the RD non-administration group, while those delivered within 7 days after stopping maternal RD were defined as the RD intravenous administration group. We examined the incidence and risk factors of RD-induced neonatal hypoglycemia by comparing these two groups. We enrolled 603 neonates in this study; 504 (83.6%) showed no neonatal hypoglycemia, while 99 (16.4%) exhibited neonatal hypoglycemia. The incidence of neonatal hypoglycemia was significantly higher (61.7%; 58/94) in the RD intravenous administration group than in the RD non-administration group (8.1%; 41/509) (p < 0.001). Binomial logistic regression analysis in the RD intravenous administration group showed that maternal age over 35 years (AOR: 3.385; 95% CI, 1.082–10.588, p = 0.036) and the interval to delivery from stopping intravenous administration of RD (AOR: 0.974; 95% CI, 0.953–0.996, p = 0.020) were independent factors associated with neonatal hypoglycemia. The cut-off value of the interval to predict the incidence of neonatal hypoglycemia was about 6 h (sensitivity 82.8%, specificity 63.9%). The incidence of neonatal hypoglycemia was significantly increased by maternal intravenous administration of RD. We newly identified maternal age (over 35 years) and the interval to delivery from stopping intravenous administration of RD (within 6 h) as independent risk factors for neonatal hypoglycemia following maternal intravenous administration of RD. In cases with these risk factors, careful blood glucose monitoring is recommended for early detection and treatment of neonatal hypoglycemia.
Tài liệu tham khảo
Takagi K, Satoh T. Is long-term tocolysis effective for threatened premature labor? J Int Med Res. 2009;37:227–39.
Verriello L, D'Amico D, Pauletto G, Gigli GL, Bergonzi P. Rhabdomyolysis caused by tocolytic therapy with ritodrine hydrochloride. Neuromuscul Disord. 2009;19:718–20.
Gezginç K, Gül M, Karatayli R, Cander B, Kanat F. Noncardiogenic pulmonary edema due to ritodrine usage in preterm labor. Taiwan J Obstet Gynecol. 2008;47:101–2.
Yasuda R, Makino Y, Matsuda Y, Kawamichi Y, Matsui H. Agranulocytosis associated with intravenous ritodrine hydrochloride therapy: two case reports by different mechanisms. J Obstet Gynaecol Res. 2012;38:574–7.
Haas DM, Benjamin T, Sawyer R, Quinney SK. Short-term tocolytics for preterm delivery - current perspectives. Int J Women's Health. 2014;6:343–9.
EUROPEAN MEDICINES AGENCY: PRAC recommends restricted use of short-acting beta-agonists in obstetric indications. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Short-acting_beta-agonists/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500148669.pdf. Accessed 20 Dec 2017.
Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev. 2014;doi:https://doi.org/10.1002/14651858.CD004352.pub3.
Otsuki K. Survey report on the actual use of ritodrine hydrochloride and side effects. Year Book of Japan Society of Perinatal and Neonatal Medicine. 2016;34:15–8.
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare: Pharmaceuticals and Medical Devices Safety Information No.285. http://www.pmda.go.jp/files/000152990.pdf. Accessed 20 Dec 2017.
Nakamura M, Hasegawa J, Arakaki T, Hamada S, Takita H, Oba T, et al. Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital. J Obstet Gynaecol Res. 2016;42:1680–5.
Yoneda S, Yoneda N, Fukuta K, Shima T, Nakashima A, Shiozaki A, et al. In which preterm labor-patients is intravenous maintenance tocolysis effective? J Obstet Gynaecol Res. 2018;44:397–407.
Williams AF. Hypoglycaemia of the newborn: a review. Bull World Health Organ. 1997;75:261–90.
Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127:575–9.
Brazy JE, Pupkin MJ. Effects of maternal isoxsuprine administration on preterm infants. J Pediatr. 1979;94:444–8.
Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after beta-sympathomimetic tocolytic therapy. J Pediatr. 1979;94:449–53.
Takagi K. Tocolytics for Management of Preterm Labor: use of β agonists as the first line Tocolytic agents. Acta obstetrica et gynaecologica Japonica. 2011;63:186–90.
Procianoy RS, Pinheiro CE. Neonatal hyperinsulinism after short-term maternal beta sympathomimetic therapy. J Pediatr. 1982;101(4):612–4.
van Lierde M, Thomas K. Ritodrine concentrations in maternal and fetal serum and amniotic fluid. J Perinat Med. 1982;10:119–24.
Gross TL, Kuhnert BR, Kuhnert PM, Rosen MG, Kazzi NJ. Maternal and fetal plasma concentrations of ritodrine. Obstet Gynecol. 1985;65:793–7.
Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD003927.pub3.
Koike K. Problems of infertility in aging women: the effects of aging on the ovarian function. Acta obstetrica et gynaecologica Japonica. 2000;52:278–81.
Ueda K. Problems of infertility in aging women: abortion. Acta obstetrica et gynaecologica Japonica. 2000;52:282–5.
Motai K, Nagata S, Watanabe T. Hypoglycemia of the neonate after maternal treatment of premature labor with ritodrine hydrochloride. Matsuyama R. C. Hosp J Med. 1989;14:131–5.
Takimoto H, Sugiyama T, Fukuoka H, Kato N, Yoshiike N. Maternal weight gain ranges for optimal fetal growth in Japanese women. Int J Gynecol Obstet. 2006;92:272–8.
Terada M, Matsuda Y, Ogawa M, Matsui H, Satoh S. Effects of maternal factors on birth weight in Japan. J Pregnancy. 2013;2013:172395. https://doi.org/10.1155/2013/172395.
Ministry of Healthy Labor and Welfare: Birth statistics. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/tokusyu/syussyo06/index.html. Accessed 20 Dec 2017.